Active, not recruitingNCT02724488
Selection Pressure and Evolution Induced by Immune Checkpoint Inhibitors and Other Immunologic Therapies
Studying Malignant germ cell tumor of the cervix uteri
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- University Health Network, Toronto
- Principal Investigator
- Lillian Siu, MDPrincess Margaret Hospital, Canada
- Enrollment
- 14 target
- Eligibility
- 18 years · All sexes
- Timeline
- 2015 – 2027
Collaborators
Princess Margaret Hospital, Canada
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT02724488 on ClinicalTrials.govOther trials for Malignant germ cell tumor of the cervix uteri
Additional recruiting or active studies for the same condition.
- RECRUITINGPHASE1NCT07519655Phase 1 Study of PF-08046033 in Advanced Solid TumorsPfizer
- RECRUITINGPHASE2NCT06177964Lerapolturev (PVSRIPO) in GBMDarell Bigner
- RECRUITINGPHASE2NCT05483400Open Label Phase 2 Basket Trial With Atezolizumab and Tiragolumab in Solid TumorsUniversity Medical Center Groningen
See all trials for Malignant germ cell tumor of the cervix uteri →